ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olezarsen

Also written as “Olezarsen”, “Cyclosporine Capsules USP (Modified) 100 mg” and “ISIS 678354”.

Its studies are mostly in Hypertriglyceridemia, led by 2 companies.

Drug pageOlezarsen: every studyAll 13 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 23, 202013 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ionis Pharmaceuticals114 open or runningphase 3since Sep 23, 2020Dec 1, 2017Mar 2027phase 3 · NCT05681351
Panacea Biotecits history only20 open or runningno phasesince Mar 2, 2010Mar 2, 2010none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ionis Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 1, 2017First study: phase 2 study in HypertriglyceridemiaFirst studyNCT03385239 · 114 enrolled · United States, Canada
  2. Sep 23, 2020Phase 3 study in Familial hyperchylomicronemia syndromeNCT04568434 · 66 enrolled · United States, Canada, France and more
  3. Jul 28, 2021Named olezarsenINNProposed as its International Nonproprietary Name in WHO's List 125 · before, ISIS 678354
  4. Oct 4, 2021Phase 3 study in HypertriglyceridemiaNCT05079919 · 617 enrolled · United States, Australia, Bulgaria and more
  5. Nov 11, 20212 phase 3 studies in Familial hyperchylomicronemia syndromeNCT05130450, NCT05185843
  6. Apr 26, 2022Phase 2 study in HypertriglyceridemiaNCT05355402 · 154 enrolled · United States, Canada
  7. Sep 20, 2022Phase 3 study in HypertriglyceridemiaNCT05552326 · 446 enrolled · United States, Argentina, Belgium and more
  8. Oct 11, 2022Phase 1 study in Healthy ParticipantsNCT05579860 · 104 enrolled · United States
  9. Nov 2, 2022Phase 3 study in HypertriglyceridemiaNCT05610280 · 1,478 enrolled · United States, Bulgaria, Canada and more
  10. Dec 25, 2022Phase 3 study in HypertriglyceridemiaNCT05681351 · 885 enrolled · United States, Argentina, Australia and more
  11. Jul 10, 2026Phase 3 study in Familial hyperchylomicronemia syndromeNCT07727538 · 12 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 3 study in HypertriglyceridemiaNCT05681351
  2. Jun 2027Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeNCT05185843
  3. Feb 2028Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeNCT05130450
  4. Aug 2030Primary completion: phase 3 study in Familial hyperchylomicronemia syndromeNCT07727538

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 Ionis Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07727538Familial hyperchylomicronemia syndrome · United States3RecruitingAug 203012
NCT05681351Hypertriglyceridemia · United States, Argentina, Australia and more3Active, not recruitingMar 2027885
NCT05610280Hypertriglyceridemia · United States, Bulgaria, Canada and more3CompletedAug 8, 20241,478
NCT05579860Healthy Participants · United States1CompletedMay 22, 2023104
NCT05552326Hypertriglyceridemia · United States, Argentina, Belgium and more3CompletedDec 17, 2024446
NCT05355402Hypertriglyceridemia · United States, Canada2CompletedMar 22, 2023154
NCT05185843Familial hyperchylomicronemia syndrome · United States, Canada, Sweden3Active, not recruitingJun 202724
NCT05130450Familial hyperchylomicronemia syndrome · United States, Canada, France and more3Active, not recruitingFeb 202860
NCT05079919Hypertriglyceridemia · United States, Australia, Bulgaria and more3CompletedOct 22, 2024617
NCT04568434Familial hyperchylomicronemia syndrome · United States, Canada, France and more3CompletedJul 14, 202366
NCT03385239Hypertriglyceridemia · United States, Canada2CompletedNov 25, 2019114

How it is read

Names in the registry

  • “Olezarsen”, 10 entries
  • “Cyclosporine Capsules USP (Modified) 100 mg”, 2 entries
  • “ISIS 678354”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.